Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxLSE:VRCI Dividend Yield % is 0.00% as of Jul. 23, 2026. The stock has 3 warning signs investors should review. Among 64 Medical Diagnostics & Research companies, Verici Dx ranks worse than 1562498.44% on this metric.
As of today (2026-07-23), the Trailing Annual Dividend Yield of Verici Dx is 0.00%.
The historical rank and industry rank for Verici Dx's Dividend Yield % or its related term are showing as below:
LSE:VRCI's Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.115 * Ranked among companies with meaningful Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Verici Dx (LSE:VRCI) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Verici Dx's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:VRCI vs TMO, DHR, IDXX: Dividend Yield % Comparison
For the Diagnostics & Research subindustry, Verici Dx's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx Dividend Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Verici Dx's Dividend Yield % falls into.
Verici Dx (LSE:VRCI) has a Dividend Yield % of 0.00% as of Jul. 23, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Verici Dx and its competitors. According to the industry distribution chart, Verici Dx ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry.
Is Verici Dx's Dividend Yield % too high?
Verici Dx's current Dividend Yield % is 0.00%. Based on the distribution chart, Verici Dx ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Verici Dx's Dividend Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #999999 out of 64 companies for Dividend Yield %. This places Verici Dx in the lower half of its industry. The industry median Dividend Yield % is 2.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Medical Diagnostics & Research company?
The median Dividend Yield % among Medical Diagnostics & Research companies is 2.12, based on 64 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Verici Dx and its competitors. For the Medical Diagnostics & Research industry, the median Dividend Yield % is 2.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verici Dx's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (LSE:VRCI) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Verici Dx (LSE:VRCI), the current Dividend Yield % is 0.00% as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:VRCI has been successfully added to your 
